R1507 + carboplatin + etoposide

R1507 + carboplatin + etoposide is a combination therapy under clinical investigation for cancer, notably advanced solid tumors. It combines **R1507**, a fully human IgG1 monoclonal antibody that targets and inhibits the insulin-like growth factor-1 receptor (IGF-1R), with **carboplatin** and **etoposide**, both of which are cytotoxic chemotherapeutic agents. R1507 works by binding to the extracellular domain of IGF-1R, leading to receptor internalization and degradation, thereby blocking IGF-mediated mitogenic and anti-apoptotic signaling. Carboplatin is a platinum-based compound that induces DNA crosslinking and apoptosis in rapidly dividing cells, while etoposide inhibits topoisomerase II, preventing DNA unwinding necessary for replication and transcription. This combination has been evaluated in phase I studies for safety, tolerability, and preliminary efficacy in advanced cancer patients[1][2][3][4][6].

Other names

robatumumab + carboplatin + etoposide